Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 1.00 |
| ▸ | BCR | P11274 | 8/20 | 1.00 |
| ▸ | PRKCA | P17252 | 6/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 3/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.63 |
| ▸ | PRKACA | P17612 | 2/20 | 0.63 |
| ▸ | PRKACG | P22612 | 2/20 | 0.63 |
| ▸ | PRKACB | P22694 | 2/20 | 0.63 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255 | 0.89 | ABL1 (0.80) | ABL1BCRPRKCACSNK2A1SRC | |
| SCHEMBL8837820 | 0.89 | PRKCA (1.00) | ABL1BCRPRKCACSNK2A1SRC | |
| SCHEMBL8837795 | 0.89 | ABL1 (0.80) | ABL1BCRPRKCACSNK2A1SRC | |
| SCHEMBL8837807 | 0.88 | PRKCA (0.79) | ABL1BCRPRKCACSNK2A1SRC | |
| SCHEMBL8837915 | 0.88 | ABL1 (0.79) | ABL1BCRPRKCACSNK2A1SRC | |
| SCHEMBL8837875 | 0.88 | ABL1 (0.78) | ABL1BCRPRKCACSNK2A1SRC | |
| SCHEMBL8966527 | 0.87 | ABL1 (0.77) | ABL1BCRPRKCACSNK2A1SRC | |
| SCHEMBL1662 | 0.87 | ABL1 (0.77) | ABL1BCRPRKCACSNK2A1SRC | |
| SCHEMBL8837778 | 0.87 | ABL1 (0.77) | ABL1BCRPRKCACSNK2A1SRC | |
| SCHEMBL8837759 | 0.86 | ABL1 (0.76) | ABL1BCRPRKCACSNK2A1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110906-A | Novel use of conjugates | 中山万汉制药有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-112079821-A | Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof | 中山万汉制药有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-112043708-A | Anti-hepatitis B use of conjugates | 中山万汉制药有限公司 | 2020-12-08 | — | — | CN | claimed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | claimed |
| CN-112110906-A | Novel use of conjugates | 中山万汉制药有限公司 | 2020-12-22 | — | — | CN | disclosed |
| CN-112079821-A | Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof | 中山万汉制药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-112043708-A | Anti-hepatitis B use of conjugates | 中山万汉制药有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20050203612-A1 | Luminal prostheses which allow for programmed and controlled delivery of mycophenolic acid or derivatives with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis and hyperplasia | AVANTEC VASCULAR CORPORATION (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1539041-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | Avantec Vascular Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050125054-A1 | Devices delivering therapeutic agents and methods regarding the same | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| US-5612340-A | ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-03-18 | — | — | US | disclosed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0672035-A1 | PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| EP-0672040-A1 | FURTHER PYRIMIDINE DERIVATIVES AND THEIR PREPARATION | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995009847-A1 | PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | disclosed |
| WO-1995009852-A1 | FURTHER PYRIMIDINE DERIVATIVES AND THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | disclosed |